http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
-
ESSA Pharma Inc. (EPIX) Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
-
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020
-
ESSA Pharma (EPIX) Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
-
ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer
-
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020
-
ESSA Pharma to Participate at Evercore ISI 3rd Annual HealthCONx Conference
-
ESSA Pharma to Participate in Upcoming Investor Conferences
-
ESSA Pharma Inc. Announces Delisting from the TSX-V
-
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 32nd EORTC-NCI-AACR Symposium
-
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
-
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
-
ESSA Pharma Inc. (EPIX) Announces Presentation of Additional Preclinical Data for EPI-7386 at ESMO
-
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
-
ESSA Pharma Inc. (EPIX) Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
-
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
-
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
-
ESSA Pharma Inc. (EPIX) Reports First Patient Dosed in Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
-
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
-
ESSA Pharma Inc. (EPIX) Highlights Therapeutic Potential of EPI-7386 at the 2020 American Association at AACR 2020 Virtual Meetings
-
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
-
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
-
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
-
ESSA Pharma Inc. (EPIX) Reports Submission of IND for EPI-7386 for Prostate Cancer and Provides Business Update
-
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
-
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
-
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
-
ESSA Pharma Grants Stock Options
-
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
ESSA Pharma Inc. (EPIX) Appoints Ari Brettman to Board Following Resignation of Otello Stampacchia from Board
-
ESSA Announces Changes to its Board of Directors
-
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
-
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
-
ESSA to Present at Ladenburg Thalmann Healthcare Conference
-
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
-
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
-
ESSA Pharma Inc. (EPIX) Anounces Proposed $36M Share Offering and Concurrent Private Placement
-
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019
-
ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective
-
ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics
-
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
-
ESSA Pharma (EPIX) Provides Update on Court Hearing to Acquire Realm Therapeutics
-
ESSA Provides Update on Court Hearing
-
ESSA Provides an Update to the Acquisition of Realm Therapeutics

